Comparing two treatment approaches for HER2-positive breast cancer before surgery
Treatments studied
This study tests two ways to treat HER2-positive breast cancer before surgery: one uses a single drug (SHR-A1811), and the other uses that drug followed by a combination (THPy). The goal is to see which approach works better at shrinking tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75 years.
- You have been diagnosed with stage II or III breast cancer that is HER2-positive (a marker that helps cancer grow).
- You have not had any prior treatment for this breast cancer.
- You are generally in good health (able to do your daily activities) and your heart, liver, and kidney function are within normal limits.
- You are not pregnant or breastfeeding, and if you can have children, you agree to use birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how your cancer responds, aiming to give you the best possible outcome.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.